Capital Health is the first hospital in New Jersey, and among the first in the United States, to use the new EMBOTRAP II Revascularization Device since its recent approval from the US Food and Drug Administration (FDA) in July. As part of its Comprehensive Stroke Center, neurosurgeons from Capital Health’s Capital Institute for Neurosciences use this next generation stent-retriever to safely remove a blood clot from an artery in the brain that is causing a stroke.
“EMBOTRAP II is the latest advance in mechanical thrombectomy for restoring blood flow to the brain and improving outcomes for patients who are suffering an ischemic stroke as a result of a large blood vessel blockage,” said Dr. Vernard Fennell, a fellowship trained cerebrovascular and endovascular neurosurgeon at Capital Institute for Neurosciences’ Stroke and Cerebrovascular Center. Dr. Fennell was also involved in some of the initial research on the device’s design. “As one of the tools that we use to treat ischemic stroke, EMBOTRAP II has a design that has been shown to trap clots that are causing the blockage of blood flow in the brain while retaining its shape, making it faster and more effective at retrieving the clot, restoring blood flow to the brain, and ultimately providing a better outcome.”
Stroke is a leading cause of disability and the fifth leading cause of death in the United States. Neurosurgeons from the Capital Institute for Neurosciences’ Stroke & Cerebrovascular Center are trained to use state-of-the-art devices such as EMBOTRAP II to provide the most advanced, comprehensive stroke care to patients in Central New Jersey and Eastern Pennsylvania. Capital Health’s Institute for Neurosciences is committed to being a leader in innovation and technology in all aspects of Neuroscience and Stroke Care.